Drugs / DSL101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07240896 | Dec 2025 → Apr 2028 expected | Wilson disease | DSciLab Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSL101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07240896 ↗ |
| Modality | Messenger RNA (mRNA) | “ATP7B mRNA/LNP (DSL101)” NCT07240896 ↗ |
| Route | Intravenous | “Subjects will receive intravenous infusions of DSL101 once every four weeks.” NCT07240896 ↗ |
| Target | ATP7B | “ATP7B mRNA/LNP (DSL101)” NCT07240896 ↗ |